DE602004032483D1 - Von Survivin abgeleitete Peptide und deren Verwendung - Google Patents
Von Survivin abgeleitete Peptide und deren VerwendungInfo
- Publication number
- DE602004032483D1 DE602004032483D1 DE602004032483T DE602004032483T DE602004032483D1 DE 602004032483 D1 DE602004032483 D1 DE 602004032483D1 DE 602004032483 T DE602004032483 T DE 602004032483T DE 602004032483 T DE602004032483 T DE 602004032483T DE 602004032483 D1 DE602004032483 D1 DE 602004032483D1
- Authority
- DE
- Germany
- Prior art keywords
- survivin
- derived peptides
- peptide
- cells
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 102000000763 Survivin Human genes 0.000 title abstract 2
- 108010002687 Survivin Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/354,090 US20040210035A1 (en) | 2002-01-30 | 2003-01-30 | Survivin-derived peptides and use thereof |
US10/715,417 US7892559B2 (en) | 2002-01-30 | 2003-11-19 | Survivin-derived peptides and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004032483D1 true DE602004032483D1 (de) | 2011-06-09 |
Family
ID=32829435
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004032483T Expired - Lifetime DE602004032483D1 (de) | 2003-01-30 | 2004-01-30 | Von Survivin abgeleitete Peptide und deren Verwendung |
DE602004016287T Expired - Lifetime DE602004016287D1 (de) | 2003-01-30 | 2004-01-30 | Von survivin abstammende peptide und deren verwendung |
DE602004025059T Expired - Lifetime DE602004025059D1 (de) | 2003-01-30 | 2004-01-30 | Von Survivin abgeleitete Peptide und deren Verwendung |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004016287T Expired - Lifetime DE602004016287D1 (de) | 2003-01-30 | 2004-01-30 | Von survivin abstammende peptide und deren verwendung |
DE602004025059T Expired - Lifetime DE602004025059D1 (de) | 2003-01-30 | 2004-01-30 | Von Survivin abgeleitete Peptide und deren Verwendung |
Country Status (16)
Country | Link |
---|---|
US (4) | US7892559B2 (de) |
EP (5) | EP2857034B1 (de) |
JP (1) | JP5121143B2 (de) |
CN (2) | CN1767848B (de) |
AT (3) | ATE454159T1 (de) |
AU (1) | AU2004208469B2 (de) |
CA (1) | CA2513104C (de) |
DE (3) | DE602004032483D1 (de) |
EA (1) | EA008026B1 (de) |
ES (2) | ES2312956T3 (de) |
HK (2) | HK1087335A1 (de) |
MX (1) | MXPA05008128A (de) |
NO (1) | NO333213B1 (de) |
NZ (1) | NZ541510A (de) |
PT (3) | PT1587532E (de) |
WO (1) | WO2004067023A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040210035A1 (en) * | 2002-01-30 | 2004-10-21 | Straten Eivind Per Thor | Survivin-derived peptides and use thereof |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
AU2004290866B2 (en) | 2003-11-19 | 2010-09-02 | Survac Aps | Proteins belonging to the BcL-2 family and fragments thereof, and their use in cancer patients |
JP4602006B2 (ja) * | 2004-06-29 | 2010-12-22 | 独立行政法人科学技術振興機構 | サバイビン由来のhla−a24結合性癌抗原ペプチド |
JP4475469B2 (ja) | 2005-01-25 | 2010-06-09 | 日本電気株式会社 | Hla結合性ペプチド、それをコードするdna断片および組み換えベクター |
AU2011203536B2 (en) * | 2005-02-04 | 2012-11-15 | Survac Aps | Survivin peptide vaccine |
DK1853305T3 (en) * | 2005-02-04 | 2014-12-01 | Survac Aps | Survivin-peptide vaccine |
AU2011203535B2 (en) * | 2005-02-04 | 2012-10-11 | Survac Aps | Survivin peptide vaccine |
US20060276423A1 (en) * | 2005-04-18 | 2006-12-07 | Rachel Altura | Survivin-directed RNA interference-compositions and methods |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
FR2891462B1 (fr) | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
ES2529193T3 (es) * | 2007-07-19 | 2015-02-17 | Health Research, Inc. | Péptidos de survivina como vacunas contra el cáncer |
US8580269B2 (en) | 2007-07-19 | 2013-11-12 | Health Research, Inc. | Survivin peptides for autoimmune therapies |
CN101981187A (zh) * | 2008-03-31 | 2011-02-23 | 株式会社生物免疫平衡 | MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法 |
PT2119726E (pt) * | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Cdca1抗原決定位胜肽及含此胜肽的疫苗 |
EP2172211B1 (de) * | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Zusammensetzung aus tumorassoziierten Peptiden und damit verbundene Antikrebsimpfung zur Behandlung von Glioblastoma (GBM) und anderen Krebsarten |
WO2011073215A2 (en) | 2009-12-14 | 2011-06-23 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
CA2821582A1 (en) | 2010-12-14 | 2012-06-21 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
BR112013023978B1 (pt) * | 2011-03-21 | 2021-09-08 | Atlantic Cancer Research Institute | Polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica |
EP2854842A4 (de) | 2012-05-25 | 2016-11-02 | Agenus Inc | Identifizierung von mhc-klasse-i-phosphopeptidantigenen von brustkrebs mittels shla-technologie und komplementärer anreicherungsstrategien |
WO2014010229A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Cdca1 epitope peptides for th1 cells and vaccines containing the same |
CN105324128B (zh) | 2013-03-27 | 2020-09-01 | 免疫疫苗技术有限公司 | 用于改善存活蛋白疫苗在癌症治疗中的功效的方法 |
MX2016006625A (es) * | 2013-11-22 | 2016-12-02 | Univ Illinois | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. |
KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
WO2016109880A1 (en) | 2015-01-06 | 2016-07-14 | Immunovaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
EP3288538A4 (de) * | 2015-05-01 | 2018-10-24 | ImmunoVaccine Technologies Inc. | Verfahren zur verstärkung einer immunreaktion anhand von depot-formenden und nicht-depot-formenden impfstoffen |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
US11160861B2 (en) | 2015-11-18 | 2021-11-02 | Immunovaccine Technologies Inc. | Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant |
GB201604755D0 (en) * | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
WO2018055060A1 (en) | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
CN110022893B (zh) | 2016-10-07 | 2023-12-29 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
US11712465B2 (en) | 2016-10-07 | 2023-08-01 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
CN117801069A (zh) | 2016-10-07 | 2024-04-02 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
SG11201906765UA (en) | 2017-03-03 | 2019-08-27 | Treos Bio Zrt | Personalised immunogenic peptide identification platform |
JP6993677B2 (ja) * | 2017-11-08 | 2022-01-13 | 学校法人日本医科大学 | 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン |
AU2019253217A1 (en) * | 2018-04-11 | 2020-10-15 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
EP3846845A1 (de) | 2018-09-04 | 2021-07-14 | Treos Bio Limited | Peptidimpfstoffe |
FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
CA3119910A1 (en) * | 2018-11-19 | 2020-05-28 | Immunovaccine Technologies Inc. | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors |
US20220064260A1 (en) * | 2018-12-14 | 2022-03-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
CN111440246B (zh) * | 2020-04-16 | 2022-03-18 | 成都仕康美生物科技有限公司 | 靶向HLA-B的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途 |
EP4410304A1 (de) * | 2021-09-24 | 2024-08-07 | Cha Vaccine Research Institute Co., Ltd | Antikrebsimpfstoffzusammensetzung mit peptiden aus tumorassoziiertem antigen und adjuvans aus lipopeptid und immunaktivem stoff sowie verwendung davon |
CN115477686B (zh) * | 2022-09-22 | 2024-01-30 | 北海黑珍珠海洋生物科技有限公司 | 一种具有美白功效的珍珠贝活性肽及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
WO1994005304A1 (en) | 1992-08-31 | 1994-03-17 | Ludwig Institute For Cancer Research | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
US5514539A (en) * | 1993-06-29 | 1996-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
WO1998022589A2 (en) * | 1996-11-20 | 1998-05-28 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
WO1999050637A2 (en) * | 1998-03-27 | 1999-10-07 | Ludwig Institute For Cancer Research | Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof |
AU768834B2 (en) * | 1998-04-01 | 2004-01-08 | Yale University | A method for selectively modulating the interactions between survivin and tubulin |
AU4990999A (en) | 1998-07-14 | 2000-02-07 | Jenner Biotherapies, Inc. | Survivin, and peptides thereof, as an anti-cancer vaccine |
JP4608184B2 (ja) * | 2001-03-14 | 2011-01-05 | ダコ デンマーク アクティーゼルスカブ | 新規なmhc分子構築物、ならびに診断および処置のためにこれらの構築物を用いる方法、ならびにmhc分子の使用 |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
US20040210035A1 (en) * | 2002-01-30 | 2004-10-21 | Straten Eivind Per Thor | Survivin-derived peptides and use thereof |
DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
AU2004290866B2 (en) | 2003-11-19 | 2010-09-02 | Survac Aps | Proteins belonging to the BcL-2 family and fragments thereof, and their use in cancer patients |
-
2003
- 2003-11-19 US US10/715,417 patent/US7892559B2/en active Active
-
2004
- 2004-01-30 AU AU2004208469A patent/AU2004208469B2/en not_active Expired
- 2004-01-30 DE DE602004032483T patent/DE602004032483D1/de not_active Expired - Lifetime
- 2004-01-30 CA CA2513104A patent/CA2513104C/en not_active Expired - Lifetime
- 2004-01-30 ES ES04706615T patent/ES2312956T3/es not_active Expired - Lifetime
- 2004-01-30 NZ NZ541510A patent/NZ541510A/en not_active IP Right Cessation
- 2004-01-30 EP EP14191676.7A patent/EP2857034B1/de not_active Expired - Lifetime
- 2004-01-30 JP JP2005518634A patent/JP5121143B2/ja not_active Expired - Lifetime
- 2004-01-30 PT PT04706615T patent/PT1587532E/pt unknown
- 2004-01-30 ES ES08163405T patent/ES2339193T3/es not_active Expired - Lifetime
- 2004-01-30 DE DE602004016287T patent/DE602004016287D1/de not_active Expired - Lifetime
- 2004-01-30 EP EP10180878.0A patent/EP2359841B1/de not_active Expired - Lifetime
- 2004-01-30 PT PT08163405T patent/PT2005966E/pt unknown
- 2004-01-30 EP EP08163405A patent/EP2005966B1/de not_active Expired - Lifetime
- 2004-01-30 EP EP04706615A patent/EP1587532B1/de not_active Expired - Lifetime
- 2004-01-30 WO PCT/DK2004/000062 patent/WO2004067023A2/en active IP Right Grant
- 2004-01-30 AT AT08163405T patent/ATE454159T1/de active
- 2004-01-30 EA EA200501206A patent/EA008026B1/ru not_active IP Right Cessation
- 2004-01-30 MX MXPA05008128A patent/MXPA05008128A/es active IP Right Grant
- 2004-01-30 AT AT09155102T patent/ATE506962T1/de active
- 2004-01-30 CN CN2004800070526A patent/CN1767848B/zh not_active Expired - Lifetime
- 2004-01-30 US US10/543,755 patent/US8318174B2/en active Active
- 2004-01-30 DE DE602004025059T patent/DE602004025059D1/de not_active Expired - Lifetime
- 2004-01-30 CN CN2010101195668A patent/CN101906148B/zh not_active Expired - Lifetime
- 2004-01-30 AT AT04706615T patent/ATE406906T1/de active
- 2004-01-30 PT PT09155102T patent/PT2092938E/pt unknown
- 2004-01-30 EP EP09155102A patent/EP2092938B1/de not_active Expired - Lifetime
-
2005
- 2005-08-29 NO NO20053999A patent/NO333213B1/no not_active IP Right Cessation
-
2006
- 2006-07-10 HK HK06107692.0A patent/HK1087335A1/xx not_active IP Right Cessation
-
2009
- 2009-06-22 HK HK09105575.3A patent/HK1126668A1/xx not_active IP Right Cessation
-
2012
- 2012-09-28 US US13/630,862 patent/US9534030B2/en not_active Ceased
-
2018
- 2018-07-19 US US16/039,999 patent/USRE48522E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE506962T1 (de) | Von survivin abgeleitete peptide und deren verwendung | |
DE602005015990D1 (de) | Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden | |
TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
AR032743A1 (es) | Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon | |
ATE348632T1 (de) | Prion protein peptide und deren verwendung | |
MXPA03001634A (es) | Polipeptido tumoral cripto. | |
CY1110134T1 (el) | Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους | |
CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
AR031250A1 (es) | Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon | |
ATE512160T1 (de) | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen | |
WO2006023598A3 (en) | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer | |
DE602004020266D1 (de) | Therapeutische und diagnostische anti-hsp 70-antikörper | |
DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
EE05293B1 (et) | RG1 polpeptiidiga seonduv antikeha, seda h?lmav immunkonjugaat ja nende kasutamine | |
NO20181511A1 (no) | Survivin-avledede peptider og bruken av dem | |
DE69828791D1 (de) | Das antigen ha-1 | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores | |
ATE435284T1 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
CY1108412T1 (el) | Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis | |
AR023794A1 (es) | Antigeno asociado con tumores | |
UY26127A1 (es) | Antígeno asociado con tumores | |
CY1111320T1 (el) | Cripto ειδικα αντισωματα | |
CO5310552A1 (es) | Compuestos para la terapia y el diagnostico de cancer de pulmon y metodos de uso de los mismos |